drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic), subcutaneous
drug_description
A human IgG1 monoclonal antibody targeting the BAFF receptor (BAFF-R/TNFRSF13C) on B cells; blocks BAFF signaling and induces B-cell depletion via immune effector functions (e.g., ADCC).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ianalumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Ianalumab (VAY736) is a human IgG1 monoclonal antibody that binds the BAFF receptor (BAFF‑R/TNFRSF13C) on B cells, blocking BAFF-mediated survival and activation signaling and inducing B‑cell depletion via immune effector functions (e.g., ADCC/CDC). This reduces B‑cell activation, differentiation to plasmablasts/plasma cells, and autoantibody production.
drug_name
Ianalumab (VAY736)
nct_id_drug_ref
NCT05624749